| Item Type | Name |
|
Concept
|
ABO Blood-Group System
|
|
Concept
|
Amino Acid Sequence
|
|
Concept
|
Blood Specimen Collection
|
|
Concept
|
Base Sequence
|
|
Concept
|
Emergency Service, Hospital
|
|
Concept
|
Colony-Forming Units Assay
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Graft Survival
|
|
Concept
|
Fractures, Spontaneous
|
|
Concept
|
Feasibility Studies
|
|
Concept
|
Neoplasm Regression, Spontaneous
|
|
Concept
|
Hematopoietic Stem Cells
|
|
Concept
|
Monoclonal Gammopathy of Undetermined Significance
|
|
Concept
|
Molecular Sequence Data
|
|
Concept
|
Myelodysplastic Syndromes
|
|
Concept
|
Neoplasm Staging
|
|
Concept
|
Safety
|
|
Concept
|
Parkinson Disease, Secondary
|
|
Concept
|
Microbial Sensitivity Tests
|
|
Concept
|
Spinal Puncture
|
|
Concept
|
Ukraine
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Salivary Proteins and Peptides
|
|
Concept
|
Smoking
|
|
Concept
|
Sensitivity and Specificity
|
|
Concept
|
Spectrophotometry, Atomic
|
|
Concept
|
Stress, Psychological
|
|
Concept
|
Skin
|
|
Concept
|
Surgical Wound Infection
|
|
Concept
|
Stem Cells
|
|
Concept
|
Smoking Cessation
|
|
Concept
|
United States
|
|
Concept
|
Multicenter Studies as Topic
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Up-Regulation
|
|
Concept
|
Neoplasms, Second Primary
|
|
Concept
|
Salvage Therapy
|
|
Concept
|
Stem Cell Transplantation
|
|
Concept
|
Case-Control Studies
|
|
Concept
|
T-Lymphocyte Subsets
|
|
Concept
|
Sequence Analysis, DNA
|
|
Concept
|
National Institutes of Health (U.S.)
|
|
Concept
|
L-Selectin
|
|
Concept
|
Hematopoietic Stem Cell Mobilization
|
|
Concept
|
Desmoplastic Small Round Cell Tumor
|
|
Concept
|
Peripheral Blood Stem Cell Transplantation
|
|
Concept
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
|
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
|
Concept
|
Sirolimus
|
|
Concept
|
Limb Salvage
|
|
Concept
|
Surveys and Questionnaires
|
|
Concept
|
National Cancer Institute (U.S.)
|
|
Concept
|
Saliva
|
|
Concept
|
Sarcoma
|
|
Concept
|
Sarcoma, Ewing
|
|
Concept
|
Severity of Illness Index
|
|
Concept
|
Tandem Mass Spectrometry
|
|
Concept
|
Acute Coronary Syndrome
|
|
Concept
|
Social Adjustment
|
|
Concept
|
Donor Selection
|
|
Concept
|
Urate Oxidase
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Tumor Lysis Syndrome
|
|
Concept
|
NK Cell Lectin-Like Receptor Subfamily K
|
|
Concept
|
Survival Analysis
|
|
Concept
|
Survivors
|
|
Concept
|
Survival Rate
|
|
Concept
|
Genes, p53
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Patient Selection
|
|
Concept
|
Secondary Prevention
|
|
Concept
|
Siblings
|
|
Concept
|
Cord Blood Stem Cell Transplantation
|
|
Concept
|
Unrelated Donors
|
|
Concept
|
Standard of Care
|
|
Concept
|
Cell Survival
|
|
Concept
|
Data Interpretation, Statistical
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Health Status
|
|
Concept
|
Longitudinal Studies
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Sclerosis
|
|
Concept
|
Neoplastic Stem Cells
|
|
Concept
|
Signal Transduction
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Mice, SCID
|
|
Concept
|
Sickness Impact Profile
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Neurotoxicity Syndromes
|
|
Concept
|
Secretory Leukocyte Peptidase Inhibitor
|
|
Academic Article
|
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
|
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
|
Academic Article
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
|
Academic Article
|
Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
|
|
Academic Article
|
Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation.
|
|
Academic Article
|
Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
|
|
Academic Article
|
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
|
|
Academic Article
|
Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
|
|
Academic Article
|
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
|
|
Academic Article
|
Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor.
|
|
Academic Article
|
Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.
|
|
Academic Article
|
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
|
|
Academic Article
|
Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations.
|
|
Academic Article
|
Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.
|
|
Academic Article
|
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
|
|
Academic Article
|
Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange.
|
|
Academic Article
|
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
|
|
Academic Article
|
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.
|
|
Academic Article
|
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.
|
|
Academic Article
|
Principles and overview of allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Relapse after allogeneic hematopoietic cell therapy.
|
|
Academic Article
|
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
|
|
Academic Article
|
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.
|
|
Academic Article
|
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
|
|
Academic Article
|
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
|
|
Academic Article
|
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
|
|
Academic Article
|
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.
|
|
Academic Article
|
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
|
|
Academic Article
|
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation for lymphoma.
|
|
Academic Article
|
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
|
|
Academic Article
|
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
|
|
Academic Article
|
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
|
|
Academic Article
|
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
|
|
Academic Article
|
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?
|
|
Academic Article
|
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
|
|
Academic Article
|
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
|
|
Academic Article
|
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol.
|
|
Academic Article
|
Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies.
|
|
Academic Article
|
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
|
|
Academic Article
|
Donor lymphocyte infusion: beauty is in the eye of the beholder.
|
|
Academic Article
|
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
|
|
Academic Article
|
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
|
|
Academic Article
|
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
|
|
Academic Article
|
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
|
|
Academic Article
|
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
|
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
|
Academic Article
|
Minimal residual disease following allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review.
|
|
Academic Article
|
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
|
|
Academic Article
|
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
|
|
Academic Article
|
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.
|
|
Academic Article
|
Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
|
|
Academic Article
|
Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation.
|
|
Academic Article
|
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
|
|
Academic Article
|
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
|
|
Academic Article
|
Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation.
|
|
Academic Article
|
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.
|
|
Academic Article
|
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
|
|
Academic Article
|
Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
|
|
Academic Article
|
Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.
|
|
Academic Article
|
High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
|
|
Academic Article
|
Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning.
|
|
Academic Article
|
Hematopoietic stem cell transplantation. Introduction.
|
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.
|
|
Academic Article
|
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
|
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
|
|
Academic Article
|
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.
|
|
Academic Article
|
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion.
|
|
Academic Article
|
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
|
|
Academic Article
|
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.
|
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
|
|
Academic Article
|
Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation.
|
|
Academic Article
|
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
|
|
Academic Article
|
Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.
|
|
Academic Article
|
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
|
|
Academic Article
|
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
|
|
Academic Article
|
Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.
|
|
Academic Article
|
Potential use of hematopoietic stem cells after radiation injury.
|
|
Academic Article
|
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
|
|
Academic Article
|
Allogeneic bone marrow transplantation for low-grade lymphoma.
|
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
|
Academic Article
|
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
|
|
Academic Article
|
Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.
|
|
Academic Article
|
Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease.
|
|
Academic Article
|
Update on checkpoint blockade therapy for lymphoma.
|
|
Academic Article
|
Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
|
|
Academic Article
|
The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma.
|
|
Academic Article
|
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research.
|
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
|
Academic Article
|
Development of severe sclerotic chronic GVHD during treatment with dasatinib.
|
|
Academic Article
|
Drug-induced parkinsonism after allogeneic bone marrow transplantation.
|
|
Academic Article
|
Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues.
|
|
Academic Article
|
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
|
|
Academic Article
|
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
|
|
Academic Article
|
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.
|
|
Academic Article
|
Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells.
|
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
|
Academic Article
|
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.
|
|
Academic Article
|
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.
|
|
Academic Article
|
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.
|
|
Academic Article
|
Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.
|
|
Academic Article
|
Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.
|
|
Academic Article
|
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
|
|
Academic Article
|
Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
|
|
Academic Article
|
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.
|
|
Academic Article
|
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.
|
|
Academic Article
|
The risk of secondary leukemias following autologous stem cell transplantation.
|
|
Academic Article
|
Blood stem cell transplantation in non-Hodgkin's lymphoma.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
|
Academic Article
|
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
|
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.
|
|
Academic Article
|
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
|
|
Academic Article
|
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.
|
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
|
Academic Article
|
Effective desensitization for a strong donor-specific HLA antibody in a case of HLA-mismatched allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
|
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
|
Academic Article
|
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
|
|
Academic Article
|
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.
|
|
Academic Article
|
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
|
|
Academic Article
|
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter.
|
|
Academic Article
|
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
|
|
Academic Article
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
|
|
Academic Article
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
|
|
Academic Article
|
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
|
|
Academic Article
|
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials.
|
|
Academic Article
|
Cognitive functioning of older adults prior to hematopoietic stem cell transplantation.
|
|
Academic Article
|
Current Status of CAR T Cell Therapy for Leukemias.
|
|
Academic Article
|
Echocardiographic predictors of new-onset atrial arrhythmias in patients undergoing hematopoietic stem cell transplantation.
|
|
Academic Article
|
CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy.
|
|
Academic Article
|
Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
|
|
Academic Article
|
Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.
|
|
Academic Article
|
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
|
|
Academic Article
|
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
|
|
Academic Article
|
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
|
|
Academic Article
|
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
|
|
Academic Article
|
Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
|
|
Academic Article
|
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
|
|
Academic Article
|
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
|
|
Concept
|
Symptom Assessment
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Historically Controlled Study
|
|
Academic Article
|
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
|
|
Academic Article
|
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
|
|
Academic Article
|
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
|
|
Academic Article
|
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
|
|
Academic Article
|
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
|
|
Academic Article
|
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
|
|
Academic Article
|
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
|
|
Academic Article
|
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.
|
|
Grant
|
Developing Immunoablative Regimens for the Engraftment of Allogeneic HSCT
|
|
Grant
|
Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
|
|
Grant
|
Optimizing the Graft-Versus-Tumor Effect in Allogeneic HSCT
|
|
Grant
|
Developing Immunoablative Regimens for the Engraftment of Allogeneic HSCT
|
|
Grant
|
Optimizing the Graft-Versus-Tumor Effect in Allogeneic HSCT
|
|
Academic Article
|
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
|
|
Academic Article
|
Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma.
|
|
Academic Article
|
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
|
|
Academic Article
|
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
|
|
Academic Article
|
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
|
|
Academic Article
|
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.
|
|
Academic Article
|
Monoclonal antibody therapy.
|
|
Academic Article
|
Renal autocrine neuropeptide FF (NPFF) signaling regulates blood pressure.
|
|
Academic Article
|
Pathologic fracture in childhood and adolescent osteosarcoma: A single-institution experience.
|
|
Academic Article
|
Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
|
|
Academic Article
|
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel.
|
|
Academic Article
|
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
|
|
Academic Article
|
Into the (Second) Valley of Death, Rode the Six Hundred.
|
|
Academic Article
|
Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation.
|
|
Academic Article
|
When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.
|
|
Academic Article
|
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
|
|
Academic Article
|
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
|
|
Academic Article
|
Late complications and long-term care of adult CAR T-cell patients.
|
|
Academic Article
|
Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis.
|
|
Academic Article
|
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
|
|
Academic Article
|
The attributable risk of smoking on surgical complications.
|
|
Academic Article
|
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.
|
|
Academic Article
|
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
|
|
Academic Article
|
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
|
|
Academic Article
|
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.
|
|
Academic Article
|
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
|
|
Academic Article
|
Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.
|
|
Academic Article
|
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
|
|
Academic Article
|
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
The graft-versus-lymphoma effect: fact, fiction, or opportunity?
|
|
Academic Article
|
Tumour lysis syndrome: new therapeutic strategies and classification.
|
|
Academic Article
|
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
|
|
Academic Article
|
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
|
|
Academic Article
|
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer.
|
|
Academic Article
|
The evolving world of tumor lysis syndrome.
|
|
Academic Article
|
Overview of non-Hodgkin's lymphoma.
|
|
Academic Article
|
Long-term physiologic and oncologic outcomes of inferior vena cava thrombosis in pediatric malignant abdominal tumors.
|
|
Academic Article
|
Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies.
|
|
Academic Article
|
Identifying and cultivating superforecasters as a method of improving probabilistic predictions.
|
|
Academic Article
|
Prevention and treatment of relapse after stem cell transplantation with immunotherapy.
|
|
Academic Article
|
Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents.
|
|
Academic Article
|
CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists.
|
|
Academic Article
|
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.
|
|
Academic Article
|
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma.
|
|
Academic Article
|
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
|
|
Academic Article
|
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.
|